Coronado Biosciences

Coronado Biosciences, City of Hope form Mustang Therapeutics

Friday, March 20, 2015

Coronado Biosciences has formed a new company, Mustang Therapeutics, in partnership with California research and treatment center City of Hope. Mustang initially will focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated the first two CAR-T cells from this partnership will begin enrollment in human clinical trials at the City of Hope this year.

[Read More]

Coronado appoints Weisman as CEO

Wednesday, January 9, 2013

Coronado Biosciences, a Burlington, Mass.-based biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, has appointed Harlan F. Weisman, M.D., as its new chairman and CEO.

[Read More]